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Abstract
AIM: To examine the cost benefit conferred by the 
perioperative administration of intravenous tranexamic 
acid (TXA) in lower limb arthroplasty.
METHODS: This study evaluates the use of TXA in 200 
consecutive lower limb arthroplasties performed in a 
single surgeon series. The initial 100 patients (control 
group) underwent surgery without perioperative admini-
stration of TXA while the subsequent 100 patients (TXA 
group) all received 1 g TXA at the time of induction 
of anaesthesia. Pre- and post-operative haemoglobin, 
platelet count, haematocrit, the use of blood product 
post-operatively, length of stay were examined. A 
financial analysis of both groups was then undertaken. 
RESULTS: The mean age of patients in both groups 
was 63 ± 13 years. There were no significant differences 
between groups in terms of gender (P = 0.47), proportion 
of total hip replacement to total knee replacement (P = 
0.25) or pre-operative haemoglobin (P = 0.43). In the 
control group, the transfusion rate was 22%. In the TXA 
group, the transfusion rate dropped to 2% (P < 0.001). 
The mean post-operative haemoglobin was 10.82 ± 1.55 
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g/dL in the control group vs 11.33 ± 1.27 g/dL in the 
TXA group (P = 0.01). The total cost of transfused blood 
products was €11055 and €603 respectively. The mean 
length of stay in the control group was 6.53 ± 5.93 d vs 
5.47 ± 4.26 d in the TXA group (P = 0.15) leading to an 
estimated financial saving of €114586. There was one 
pulmonary embolus in the control group and one deep 
venous thrombosis in the TXA group.
CONCLUSION: Intravenous TXA reduces blood loss in 
lower limb arthroplasty. This leads to lower transfusion 
rates, shorter length of stay in hospital and significant 
financial savings. 
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Core tip: Worldwide the demand for lower limb arth-
roplasty procedures is increasing in the context of a 
diminishing economic climate. Total hip replacement 
and total knee replacement have traditionally been 
associated with large volume blood loss and the need for 
transfusion. Use of perioperative intravenous tranexamic 
acid (TXA) has been shown to be a cost effective 
measure, which reduces the need for transfusion. In this 
study, TXA was found to significantly reduce the number 
of patients requiring blood transfusion post-operatively, 
which has both clinical and economic significance.
McGoldrick NP, O’Connor EM, Davarinos N, Galvin R, Quinlan 
JF. Cost benefit analysis of the use of tranexamic acid in primary 
lower limb arthroplasty: A retrospective cohort study. World J 
Orthop 2015; 6(11): 977-982  Available from: URL: http://www.
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INTRODUCTION
An aging population globally, coupled with an expansion 
of the indications for total hip replacement (THR) and 
total knee replacement (TKR) has meant that the 
demand for lower limb arthroplasty is expected to 
increase in the future[1]. Against this, the economic 
climate worldwide has resulted in reduced healthcare 
funding whilst expecting increased productivity from the 
orthopaedic surgeon.
Surgical procedures such as THR and TKR may 
require allogeneic blood transfusion post-operatively[2,3]. 
Perioperative transfusion of blood products not only adds 
expense to the procedure, but also places the patient at 
increased risk of wound infection, immune suppression 
and allergy, transfusion-related lung injury and trans-
mission of viral pathogens[4-6]. Efforts have therefore 
focused on maintaining post-operative haemoglobin 
levels and minimizing the need for blood transfusions. 
Such measures may reduce overall surgical morbidity 
and length of in-hospital admission, while minimizing the 
burden of additional blood tests.
Perioperative tranexamic acid (TXA) has emerged 
as a useful adjunctive agent in reducing blood loss 
and the need for blood transfusion in lower limb arth-
roplasty. TXA is a synthetic derivative of the amino 
acid lysine, and exerts antifibrinolytic activity by comp­
etitively binding the lysine sites on plasminogen. It is 
thought that this makes blood clots more resistant to 
degradation, thereby preventing further blood loss.
Several recent studies have reported favourable 
outcomes for intravenous administration of TXA in both 
THR and TKR[7,8]. Studies examining oral and topical 
administration of TXA have also demonstrated promising 
results[9,10].
The primary aim of this study was to evaluate 
whether the use of intravenous TXA in elective primary 
THR and TKR in a single surgeon series resulted in 
reduced transfusion rate of packed red blood cells. 
Secondary aims included examining the effect of TXA on 
post-operative haemoglobin, haematocrit and platelet 
count, length of stay in hospital, rate of deep venous 
thrombosis (DVT) and pulmonary embolism and to 
assess whether its use is cost effective.
MATERIALS AND METHODS
This study was a retrospective review of a cohort of 200 
consecutive primary total knee and hip replacements 
performed by a single orthopaedic surgeon at a single 
institution between September 2013 and March 2015. 
The initial 100 joints were all performed without 
perioperative administration of TXA (control group). 
The subsequent 100 joints were all performed with addi-
tional perioperative TXA (TXA group). Revision joints, 
arthroplasties performed for fracture, and simultaneous 
bilateral procedures were excluded from the analysis. 
Preoperative antibiotic prophylaxis followed local 
institutional protocol and consisted of intravenous 
cefuroxime, or alternatively teicoplanin if there was a 
history of cephalosporin or penicillin allergy. Vancomycin 
was utilised in select cases where there was a history 
of Methicillin Resistant Staphylococcus Aureus (MRSA) 
present. Preoperative antibiotics were administered 
at induction of anaesthesia, within one hour of skin 
incision.
All THRs were performed following a uniform tech-
nique using anterolateral approach to the joint. Both 
uncemented and cemented techniques were utilised as 
determined by the operating surgeon. All TKRs were 
performed through a medial parapatellar approach to 
the knee. One gram of TXA was administered parentally 
at the time of preoperative antibiotic administration 
in the TXA group. Intraoperative surgical drains were 
placed routinely in all joints, and removed on the 
first post-operative day. DVT prophylaxis consisted of 
thrombo-embolic deterrent stockings worn for 6 wk 
post-operatively and chemical prophylaxis consisting of 
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subcutaneous low molecular weight heparin for three 
days while an in-patient on the ward. Oral rivaroxaban 
was then commenced on the fourth post-operative 
day and continued until the end of the second week 
post­operatively for TKR, and the end of the fifth week 
post-operatively for THR, as per National Institute for 
Health and Care Excellence guidelines. On the second 
post-operative day, a full blood count was performed. 
The hospital transfusion protocol was initiated where 
a patient’s haemoglobin was less than 8 g/dL or the 
patient was symptomatic with anaemia. 
The following variables were ascertained following 
retrospective review of data: Age, gender, pre-operative 
and post-operative haemoglobin, pre-operative and 
post-operative haematocrit, pre-operative and post-
operative platelet counts, tranfusions of blood product, 
length of stay in days and thrombotic complications 
including DVT or pulmonary embolus.
In consultation with our hospital blood bank and 
purchasing department, the cost of a vial of 1 g of TXA 
was determined at €0.75 at our institution. One unit 
of packed red blood cells cost €201, and a single “bed­
day used” (BDU) at our institution was valued at €1081. 
“Bed­days used” is a measure of hospital activity. A 
single BDU may be defined as a patient occupying an 
in-patient bed for all or part of one 24-h period. All 
figures were correct in respect of 2015. 
Descriptive statistics were used to represent the 
data including proportions, means and standard devi-
ations. Independent sample t-tests were used to assess 
continuous outputs, and two sample tests of proportion 
were used for binary outcomes. Statistical analysis was 
performed using Stata statistical software package, 
version 13 (StataCorp, Texas, United States). A value of 
P < 0.05 was considered to be statistically significant.
RESULTS
A total of 200 patients were included in this study. 
One hundred patients were included in the control 
group, who did not receive perioperative TXA. One 
hundred patients were included in the TXA group, who 
received TXA at the time of surgery. The average age of 
participants in both groups was 63 ± 13 years. Table 1 
displays the baseline characteristics of patients. There 
were no statistically significant differences between the 
groups across all variables at baseline. The control group 
(n = 100) comprised 40 TKR and 60 THR. The TXA 
group (n = 100) consisted of 48 TKR and 52 THR. 
Primary outcome - proportion of patients requiring 
transfusion
There was a highly significant difference between the 
groups (P < 0.001) in the proportion of patients who 
required transfusion following surgery (22 patients 
in the control group vs 2 patients in the TXA group). 
However, the number of units of blood received by 
those individuals that required transfusion did not differ 
significantly between the groups (P = 0.34).
Secondary outcomes
Table 2 indicates that there were significant differences 
in haemoglobin and haematocrit levels between the 
groups following surgery (P = 0.01). Differences in 
post-operative platelet counts between the groups were 
not statistically different (P = 0.25). The mean length 
of stay in hospital, equivalent to BDUs, for the TXA 
group was 5.47 ± 4.26 d vs 6.53 ± 5.92 d for patients 
in the control group, although this difference was not 
statistically significant (P = 0.15).
In the control group, one patient developed multiple 
pulmonary emboli on the second post-operative day 
following TKR. In the TXA group, one patient developed 
a DVT in the peroneal vein one week post-operatively 
following TKR. Both patients recovered uneventfully.
Two patients in the TXA group required blood 
transfusion. One patient was a 72-year-old lady who 
underwent uneventful left TKR. Her pre-operative hae-
moglobin dropped from 10.4 g/dL to 7.4 g/dL. Although 
asymptomatic, she activated the transfusion protocol 
and was transfused two units of blood. The second 
patient transfused blood was a 78-year-old lady who 
underwent uneventful right THR. She had a background 
history of a myelodysplastic syndrome and B12 
deficiency. She was transfused perioperatively on the 
advice of the haematology service. 
Cost analysis
This study analyzed the financial benefit of TXA in terms 
of reduction in transfusion rate and reduction in length 
of stay in hospital. At a cost of €0.75 per 1 g of TXA, the 
total cost burden for use of TXA for 100 arthroplasties 
was calculated at €75. There was a 20% difference in 
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Control group 
(n  = 100)
TXA group 
(n  = 100)
P  value
Male/female    49/51   44/56 0.47
Age in years   62.57 ± 12.14   62.9 ± 12.6 0.86
THR/TKR    60/40   52/48 0.25
Pre-operative Hgb 13.61 ± 1.42 13.77 ± 1.41 0.43
Pre-operative Hct   0.41 ± 0.04   0.41 ± 0.04 0.32
Pre-operative platelets 253.01 ± 55.87 256.85 ± 69.75 0.67
Table 1  Patient demographics
THR: Total hip replacement; TKR: Total knee replacement; Hgb: 
Haemoglobin; Hct: Haematocrit; TXA: Tranexamic acid.
Control group
(n  = 100)
TXA group 
(n  = 100)
P  value
Post-operative Hgb 10.82 ± 1.55 11.33 ± 1.27 0.01
Post-operative Hct   0.32 ± 0.05   0.34 ± 0.04 0.01
Post-operative platelets 204.32 ± 44.68 212.22 ± 52.49 0.25
Mean length of stay in 
hospital in days
  6.53 ± 5.92   5.47 ± 4.26 0.15
Table 2  Differences between the groups following surgery
Hgb: Haemoglobin; Hct: Haematocrit; TXA: Tranexamic acid.
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patients transfused in the control group (n = 22) vs 
the TXA group (n = 2). This has clinical significance 
for the patient. With a drop in the number of patients 
transfused from 22% to 2%, patients were at reduced 
risk of recognized transfusion related complications. 
These figures are similar to the findings of Tuttle et 
al[10] and Gillette et al[26] who have reported transfusion 
rates post TXA of 17.5% vs 5.5% and 21.6% vs 8.9%, 
respectively. 
Statistically significant differences were also found 
between pre-operative and post-operative haemoglobin 
(P = 0.01) and haematocrit (P = 0.01). Higher post-
operative haemoglobin may reduce the number of 
laboratory tests performed during admission, while also 
reducing patient fatigue, hypotensive episodes, and 
length of stay in hospital[26]. This may result in improved 
savings in overall cost.
Financial savings may also be made in terms of the 
cost of blood products, the expense of additional blood 
tests and laboratory labour, and the overall length of 
stay in hospital. The use of TXA in this series resulted 
in estimated savings of the cost of blood products of 
€104.52 per patient. Although the difference in length 
of stay in hospital between the control and TXA groups 
only trended towards statistical significance (P = 0.15), 
in financial terms there was a significant difference. 
Patients in the TXA group left hospital on average one 
day earlier than those in the control, with estimated 
savings of €1145.86 per patient. Larger studies may 
demonstrate statistical difference in terms of length of 
stay. Nevertheless, these findings support the growing 
body of evidence supporting the cost effectiveness of 
both intravenous and topical formulations of TXA[10,26]. 
Recent evidence further suggests TXA is also safe in 
high-risk arthroplasty patients[27].
There are potential limitations to this study. The 
findings of this study are inherently limited by its retro­
spective nature. Moreover, patients were not randomized 
into either the control or TXA groups, and this potentially 
introduces a selection bias. However, the 200 patients 
included in this analysis were consecutive, and underwent 
arthroplasty following a standardized technique, and 
in a single surgeon series. Additionally, no statistically 
significant differences in baseline variables between the 
groups were found. 
In conclusion, the addition of perioperative intr-
avenous TXA has been shown to reduce the rate of 
blood transfusion post-operatively while also generating 
considerable cost savings. 
COMMENTS
Background
Hip and knee arthroplasty can potentially result in large volume blood loss, with 
the consequent need for transfusion of blood products. This carries increased 
risk to the patient, while also is a costly intervention. Antifibrinolytic agents such 
as tranexamic acid (TXA) were originally described in the trauma setting to 
prevent blood loss. 
transfusion rate between the control and TXA group, 
in favour of the latter. A total of 55 units of blood were 
transfused in the control group, in contrast to 3 units 
of blood in the TXA group. With a cost of €201 per unit 
of packed red cells, we therefore estimated the savings 
in terms of transfusion following TXA administration at 
€10452. When this figure was offset against the cost of 
TXA, we estimated overall savings of €10377, equivalent 
to €103.77 per patient.
On average, the control group remained in hospital 
for 6.53 d, equivalent to 653 BDUs in total for this 
cohort. The TXA group averaged 5.47 d, or 547 BDUs in 
total in hospital. It was therefore calculated that for 100 
patients given TXA perioperatively, a total of 106 d were 
saved, at a cost of €1081 per BDU. On this basis, we 
estimated savings of €114586, or €1145.86 per patient. 
Table 3 summarizes our cost analysis.
DISCUSSION
Elective THR and TKR are among the most common 
surgical procedures that may lead to considerable blood 
loss requiring transfusion[11,12]. Blood loss following lower 
limb arthroplasty remains a concern for orthopaedic 
surgeons, although the rates of significant blood loss 
have improved over the past quarter of a century[13]. 
Despite this, blood losses of up to 1500 mL or higher 
following TKR have been reported[14]. 
Orthopaedic surgeons have generally tended to 
minimize the use of allogeneic blood transfusion in 
THR and TKR on the basis of concerns for potentially 
serious complications including sepsis[15], increased 
length of stay in hospital[16], and mortality[17]. Efforts 
have therefore focused on the use of pharmacological 
agents and other methods to minimize blood loss. 
Autologous transfusion[18], cryotherapy[19], hypotensive 
anaesthesia[20], fibrin tissue adhesive[21] and erythr-
opoietin alpha[22] have been studied in this regard.
The first reported successful use of TXA in knee 
arthroplasty by Benoni et al[23] in 1995 has led to incr-
eased interest in the use of antifibrinolytics in lower limb 
arthroplasty. A number of studies including retrospective 
and systematic reviews have supported the use of 
TXA in arthroplasty[8,9,24,25]. This study examined the 
affect of perioperative intravenous TXA on blood loss 
in lower limb arthroplasty. A statistically significant 
difference (P < 0.001) was identified in the number of 
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Control group
(n  = 100)
TXA group
(n  = 100)
Difference
No. of patients transfused 22 2 20
No. of units transfused 55 3 52
Total cost of transfusion €11055 €603 €10452
BDU 653 547 106
Total cost of BDU €705893 €591307 €114586
Table 3  Cost analysis
BDU: Bed days used; TXA: Tranexamic acid.
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 COMMENTS
Research frontiers
There has been increased interest among in the use of TXA as a means of 
reducing blood loss in lower limb arthroplasty. Concerns remain, however, 
regarding possible increased risk of thromboembolic disease.
Innovations and breakthroughs
In a large single surgeon series of 200 consecutive lower limb arthroplasties, 
the perioperative use of TXA resulted in significant financial savings. There was 
no increased rate of thromboembolic disease following the use of TXA.
Applications
In a time of increasing demand being placed on diminishing health resources, 
measures that result in cost savings should be encouraged. However, care 
must be taken to ensure that the use of newer agents is safe to patients. 
Perioperative TXA appears to provide a favourable cost-benefit profile, while 
also being safe in lower limb arthroplasty. Further study is required to evaluate 
the thromboembolic risk of TXA in lower limb arthroplasty.
Terminology
TXA is an abbreviation for tranexamic acid, an antifibrinolytic agent. It stabilizes 
clot by competitively binding to plasminogen.
Peer-review
This is a good article.
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